Literature DB >> 15790598

A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels.

Elizabeth C Wolstencroft1, Virginia Mattis, Anna A Bajer, Philip J Young, Christian L Lorson.   

Abstract

Spinal muscular atrophy (SMA) is caused by homozygous loss of the survival motor neuron (SMN1) gene. In virtually all SMA patients, a nearly identical copy gene is present, SMN2. SMN2 cannot fully compensate for the loss of SMN1 because the majority of transcripts derived from SMN2 lack a critical exon (exon 7), resulting in a dysfunctional SMN protein. Therefore, the critical distinction between a functional and a dysfunctional SMN protein is the inclusion or the exclusion of the exon 7 encoded peptide. To determine the role of the 16 amino acids encoded by SMN exon 7, a panel of synthetic mutations were transiently expressed in SMA patient fibroblasts and HeLa cells. Consistent with previous reports, the protein encoded by SMN exons 1-6 was primarily restricted to the nucleus. However, a variety of heterologous sequences fused to the C-terminus of SMN exons 1-6 allowed mutant SMN proteins to properly distribute to the cytoplasm and to the nuclear gems. These data demonstrate that the SMN exon 7 sequence is not specifically required, rather this region functions as a non-specific 'tail' that facilitates proper localization. Therefore, a possible means to restore additional activity to the SMNDelta7 protein could be to induce a longer C-terminus by suppressing recognition of the native stop codon. To address this possibility, aminoglycosides were examined for their ability to restore detectable levels of SMN protein in SMA patient fibroblasts. Aminoglycosides can suppress the accurate identification of translation termination codons in eukaryotic cells. Consistent with this, treatment of SMA patient fibroblasts with tobramycin and amikacin resulted in a quantitative increase in SMN-positive gems and an overall increase in detectable SMN protein. Taken together, this work describes the role of the critical exon 7 region and identifies a possible alternative approach for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790598     DOI: 10.1093/hmg/ddi131

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  51 in total

Review 1.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

2.  Discovery, synthesis, and biological evaluation of novel SMN protein modulators.

Authors:  Jingbo Xiao; Juan J Marugan; Wei Zheng; Steve Titus; Noel Southall; Jonathan J Cherry; Matthew Evans; Elliot J Androphy; Christopher P Austin
Journal:  J Med Chem       Date:  2011-08-19       Impact factor: 7.446

3.  Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy.

Authors:  Virginia B Mattis; Cheng-Wei Tom Chang; Christian L Lorson
Journal:  Neurosci Lett       Date:  2012-07-20       Impact factor: 3.046

4.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 5.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

Review 6.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

7.  Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs.

Authors:  Till Geib; Klemens J Hertel
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

Review 8.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

9.  Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model.

Authors:  Virginia B Mattis; Allison D Ebert; Marina Y Fosso; Cheng-Wei Chang; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2009-07-21       Impact factor: 6.150

10.  Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA.

Authors:  Virginia B Mattis; Marina Y Fosso; Cheng-Wei Chang; Christian L Lorson
Journal:  BMC Neurosci       Date:  2009-11-30       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.